New Premium Alert (NASDAQ: PETV) Trading Heavy Premarket! (Very Bullish)

New Premium Alert (NASDAQ: PETV) Has 450% Upside This $.87 Biomedical Stock Has [$5.00 Analyst Price Target!]( 10XProTrader Member, Kevin Vander here with "10XProTrader" delivering your new premium breakout alert for Thursday 12/21 trading session is PetVivo Inc. (NASDAQ: PETV). Are you watching PETV right now? The stock is trading premarket. This is a very bullish signal! PETV shares could sky-rocket based on Wall Streets most respected publication, CNN Markets mentions Analyst 12-month target price of $5.00/shr. Interested in a stock that has a staggering [450% upside]( according to analyst Interested in a stock that a majority of the ["Insiders"]( are buying their own stock? When you come across a stock that has heavy insider buying, you need to stop and think to yourself. Do they know something that YOU don't know? [See Here]( PetVivo Inc. (NASDAQ: PETV) is based in Minneapolis, Minnesota. It is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals. PetVivo Inc. (NASDAQ: PETV) Business Description The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals such as dogs and horses. Most of our technology was developed for human biomedical applications, and we intend to leverage the investments already expended in their development to commercialize treatments for horses and companion animals in a capital and time-efficient way. Many of the Company’s products are derived from proprietary biomaterials that simulate a body’s cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions which incorporate such “tissue building blocks” as collagen, elastin, and proteoglycans such as heparin. Since these are naturally-occurring in the body, we believe they have an enhanced biocompatibility with living tissues compared to synthetic biomaterials such as those based upon alpha-hydroxy polymers (e.g PLA, PLGA, and the like), polyacrylamides, and other “natural” biomaterials that may lack the multiple proteins incorporated into our biomaterials. The Company has several bullish catalysts in the pipeline and is on the verge of disrupting a $11 Bln space and has been making major strides with blockbuster product pipeline and intellectual property portfolio producing a strong catalyst for incredible upside potential! CATALYST - Intellectual Property is a Bullish Catalyst For PetVivo Inc. (NASDAQ: PETV) Innovation A potential catalyst that provides a very bullish outlook is (NASDAQ: PETV) intellectual property (“IP”) portfolio is comprised of patents, patent applications, trademarks, and trade secrets. We have issued ten United States Patents. In addition to the United States patent portfolio, we also have nine patents granted in key markets around the world including Canada, Australia, and countries within the European Union. We believe we have developed a broad and deep patent portfolio around our biomaterials and manufacturing processes in addition to the application of these biomaterials for use as medical devices, medical device coatings, and pharmaceutical delivery devices. The Company secures other technological know-how by trade secret law and also possesses several trademarks that are either registered or protected pursuant to trademark common law. CATALYST - PetVivo Inc. (NASDAQ: PETV) 10 United States Patents Filed - 10,967,104 – Encapsulated or Coated Stent Systems - 10,850,006 – Protein Biomaterials and Bioacervates and Methods of Making and Using Thereof - 10,744,236 – Protein Biomaterial and Biocoacervate Vessel Graft Systems and Methods of Making and Using Thereof - 10,016,534 – Protein Biomaterial and Biocoacervate Vessel Graft Systems and Methods of Making and Using Thereof - 9,999,705 – Protein Biomaterials and Bioacervates and Methods of Making and Using Thereof - 9,107,937 – Wound Treatments with Crosslinked Protein Amorphous Biomaterials - 8,623,393 – Biomatrix Structural Containment and Fixation Systems and Methods of Use Thereof - 8,529,939 – Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof - 8,465,537 – Encapsulated or Coated Stent Systems - 8,153,591 – Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof CATALYST - PetVivo Inc. (NASDAQ: PETV) Has Been Granted Nine Foreign Patents in Certain Jurisdictions, And Has Seven Patent Applications Pending in the U.S. And Certain Foreign Jurisdictions. A potential catalyst that provides a very bullish outlook is (NASDAQ: PETV) has been granted nine foreign patents in certain jurisdictions, and they have seven patent applications pending in the U.S. and certain foreign jurisdictions. To maximize the strength and value of our patent portfolio, many of the claims use the transitional term “comprising”, which is synonymous with “including” This use of transitional language is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. Our patents also include method claims covering many of the applications and uses of the biomaterials as medical devices and drug delivery systems. We believe our intellectual property portfolio strongly protects our proprietary technology, including the composition of raw elements used to produce our formulations, the fabricated biomaterials, and their application in end products, thereby making our material and devices much more attractive to industry partners. We will seek to protect our products and technologies through a combination of patents, regulatory exclusivity, and proprietary know-how. Our goal is to obtain, maintain and enforce patent protection for our products, formulations, processes, methods, and other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current compounds and any future compounds developed. We also strenuously protect our proprietary information and proprietary technology through a combination of contractual arrangements, trade secrets, and patents, both in the United States and abroad. However, even patent protection may not always afford us complete protection against competitors who seek to circumvent our patents.  We depend upon the skills, knowledge, and experience of our scientific and technical personnel, including those of our company, as well as that of our advisors, consultants, and other contractors, none of which is patentable. To help protect our proprietary know-how, which may not be patentable, and inventions for which patents may be difficult to obtain or enforce, we rely on trade secret protection and confidentiality agreements to protect our interests. To this end, we generally require all of our employees, consultants, advisors, and other contractors to enter into confidentiality agreements that prohibit disclosure of confidential information and, where applicable, require disclosure and assignment of ownership to us of the ideas, developments, discoveries, and inventions important to our business. CATALYST - Investing.com Technical Opinion Rating Issued PETV a Bullish STR∙ONG B∙UY Rating! A big catalyst that could potentially send shares vertical is Wall Streets Respected Technical Analysis site Investing.com just issued PETV a "Bullish STR∙ONG B∙UY Rating", which could be signaling a breakout to the upside. "Key Highlights For Our Fiscal Year Ended March 31, 2023" - Revenues Sky-Rocketed by 8X...increased to $917,162 in fiscal 2023, compared to revenues of $115,586 for our fiscal year ended March 31, 2022 (“fiscal 2022”); - Entered into an exclusive distribution agreement (“Distribution Agreement”) with MWI Veterinary Supply, a leading distributor of animal health products and a subsidiary of AmerisourceBergen (“MWI”) in June 2022. We recognized revenues from product sales under the Distribution Agreement of $636,345 or 69% of total revenues for the year ended March 31, 2023; - Increased brand awareness and market awareness by participating in several key national trade shows and conferences, including having Dr. Joseph Manning, DVM, the Company’s Senior Technical Veterinarian present on the use of Spryng™ at the American Association of Equine Practitioners Annual Conference in November 2022; - Reported results on the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection of Spryng™ into the stifle joint of dogs with suspected cruciate ligament damage or tear (similar to an anterior cruciate ligament (“ACL”) tear in humans) in March 2023. The preliminary results demonstrated that Spryng™ may be a viable alternative for medical management of dogs with an ACL injury; and    - Signed a lease agreement for a new production and warehouse space in Edina, Minnesota in January 2023. We plan to have this facility operational in the fourth quarter of our fiscal year ending March 31, 2024 (“fiscal 2024”). - Strong IP portfolio with ten in the United Stats and nine foreign issued patents, and currently seven pending patents in the United States. - FDA premarket approval or clearance not required for veterinary medical devices making it much easier to bring to market and capitalize. Why Are Smart Investors Researching PetVivo (NASDAQ: PETV)? Heavy Insider Buying: When the insiders of the company are buying their own stock, that generally means that they are banking on the stock going much higher. Analyst Price Target: The current price of the stock is approx $.87, and the 12-month analyst target price is a staggering $5.00 per share representing an enormous 450% upside. Spryng™ with OsteoCushion™ Technology is within a booming industry that continues to increase in growth, need, and sales. Osteoarthritis market: Osteoarthritis (OA) affects 1 out of 4 dogs and over half of all horses. This is an addressable opportunity in companion animal OA therapeutics market. U.S. veterinary care and product estimated sales in 2021 was $11 Bln. Pet ownership: Pets are a notable part of the cultural landscape, with 70% of US households owning a pet. In the US there are 69 Mln dogs and approximately 7.2M horses. Pet Market: US pet spend increased from $103.6 Bln in 2020 to $123.6 Bln in 2021. Positioned to Scale: PetVivo’s new facility, positioned to scale, has capacity to produce up to 500K units annually, equalling up to $100 Mln in revenue. Strong Product Pipeline: With a robust pipeline of 17 products at different stages of development and commercialization, Innovative Approach To Market: PetVivo’s strategy focuses on veterinary medical devices which do not require FDA premarket approval, creating a faster path to market. Conclusion: Between the [analyst price target]( being a staggering 450% higher than the current price, and the heavy [insider buying]( happening, I'm extremely bullish on (NASDAQ: PETV). I am urging all of our 10X members to add (NASDAQ: PETV) to the top of your watch list right now, and have it pulled up on your trading screen this morning at the opening bell! 10X Your Wealth, Kevin Vander Publisher, 10XProTrader.com Investment Research You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2023 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2023 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate information. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not except stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.